Showing results (131-140 of 278) with videos related to
Sort By:
Pageof 28
NPJ Vaccines|August 4, 2022
Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humansShiwei Xu, Margaret C Carpenter, Rachel L Spreng, et al.Plos One|July 21, 2017
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, et al.Molecular Therapy. Nucleic Acids|April 12, 2019
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus MacaquesNorbert Pardi, Celia C LaBranche, Guido Ferrari, et al.Plos Pathogens|March 15, 2021
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection riskErica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, et al.Clinical and Vaccine Immunology : CVI|August 18, 2017
Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant MacaquesBonnie Phillips, Genevieve G Fouda, Josh Eudailey, et al.Viruses|September 28, 2024
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune ResponsesYing Huang, Shomoita Alam, Erica Andersen-Nissen, et al.Plos Pathogens|June 20, 2024
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functionsCamille N Pierre, Lily E Adams, Jaclyn S Higgins, et al.Proceedings of the National Academy of Sciences of the United States of America|March 9, 2005
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infectionMichael R Betts, Barbara Exley, David A Price, et al.Vaccine|November 11, 2008
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trialPaul Spearman, Spyros Kalams, Marnie Elizaga, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 4, 2016
Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated SubjectsYunda Huang, Guido Ferrari, Galit Alter, et al.Pageof 28